{"slideshow_credits": null, "snippet": "While Roche's chairman claims that the Swiss drug maker has other options if its Illumina takeover bid fails, it is not clear that the alternatives will prove as attractive.", "abstract": "While Roche's chairman claims that the Swiss drug maker has other options if its Illumina takeover bid fails, it is not clear that the alternatives will prove as attractive.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "DE LA MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}], "original": "By MICHAEL J. DE LA MERCED"}, "web_url": "http://dealbook.nytimes.com/2012/03/06/weighing-roches-alternatives-to-an-illumina-deal/", "lead_paragraph": null, "headline": {"main": "Weighing Roche's Alternatives to an Illumina Deal", "kicker": "DealBook"}, "_id": "4fd3a3898eb7c8105d8ece7b", "word_count": "490", "multimedia": [], "pub_date": "2012-03-06T16:53:12Z", "source": "The New York Times", "news_desk": null, "keywords": [], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}